Influence of Metformin on Metabolic Syndrome in Patients With Coronary Artery Disease
10.3760/cma.j.issn.1008-6706.2010.01.021
- VernacularTitle:二甲双胍对冠心病患者代谢综合征的影响
- Author:
Huafa CHEN
;
Jianqiao TAN
;
Ronghui ZHOU
;
Keyun ZHU
;
Weiguo TAO
;
Zhuanhe LIANG
- Publication Type:Journal Article
- Keywords:
Coronary disease;
Metabolic syndrome;
Metformin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2010;17(1):44-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the influence of metformin on metabolic syndrome in patients with coronary artery disease.Methods 52 patients with coronary artery disease and metabolic syndrome were randomly assigned into 2 groups.the control group with 20 cases and the study group with 32 cases.All the patients were treated with standard coronary artery disease therapy and meanwhile the study group was administered with metformin in addition to the basic therapy above.The follow-up time is one year.FPG,2h postprandial glucose,FINS,TG,TC,HDL-C,insulin resistance index and other standards were compared before and after the therapy,and between the 2 groups when the observation was finished.The rate of cardiovascular events was also compared between the 2 groups.Results Compared with the control group,the study group had lower levels of FPG,2h postprandial glucose,FINS,TG and insulin resistance index when the therapy was completed(P<0.05),and the rate of cardiovascular events was also lower(P<0.05).Conclusion Metformin could lower the levels of glucose,FINS,BMI,TG and insulin resistance index in patients with coronary artery disease and metabolic syndrome.Thus,it could reduce and undermine cardlovascular risk factors,protect the cardiovascular system,reduce the rate of cardiovascular events,which fully benefits the patients.
